Last update 08 Jan 2025

Beijing Suncadia Pharmaceuticals Co., Ltd

Subsidiary Company|
2019|
Beijing Shi, China

Overview

Basic Info

Introduction
Founded in 2019 in the Yizhuang district, Beijing Suncadia Pharmaceuticals Co., Ltd is an affiliate of the Jiangsu Hengrui Medicine Co., Ltd. The parent company, which was established in 1970, specializes in the innovation, development, production, and marketing of high-quality pharmaceutical products. It made its debut on the Shanghai Stock Exchange in the year 2000.

Tags

Cardiovascular Diseases
Nervous System Diseases
Endocrinology and Metabolic Disease
Antibody
Small molecule drug
Monoclonal antibody

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Endocrinology and Metabolic Disease3
Nervous System Diseases2
Neoplasms1
Top 5 Drug TypeCount
Small molecule drug2
Biological products1
Chemical drugs1
Antibody1
Monoclonal antibody1
Top 5 TargetCount
FXIa(Factor XIa)1
ANGPTL3(Angiopoietin like 3)1
SUR1(Sulfonylurea receptor 1)1

Related

6
Drugs associated with Beijing Suncadia Pharmaceuticals Co., Ltd
SHR-1918
Target
ANGPTL3
Mechanism
ANGPTL3 inhibitors
Active Org.
Beijing Suncadia Pharmaceuticals Co., Ltd [+1]
Originator Org.
Beijing Suncadia Pharmaceuticals Co., Ltd
Active Indication
Homozygous familial hypercholesterolemia [+1]
Inactive Indication-
Drug Highest PhasePhase 3
First Approval Ctry. / Loc.-
First Approval Date-
HRS-8179
Target
SUR1
Mechanism
SUR1 inhibitors
Active Org.
Beijing Suncadia Pharmaceuticals Co., Ltd
Originator Org.
Beijing Suncadia Pharmaceuticals Co., Ltd
Active Indication
Brain Edema [+2]
Inactive Indication-
Drug Highest PhasePhase 2/3
First Approval Ctry. / Loc.-
First Approval Date-
SHR-2004
Target
FXIa
Mechanism
factor XIa inhibitors
Active Org.
Beijing Suncadia Pharmaceuticals Co., Ltd
Originator Org.
Beijing Suncadia Pharmaceuticals Co., Ltd
Active Indication
Ovarian Cancer [+6]
Inactive Indication-
Drug Highest PhasePhase 2
First Approval Ctry. / Loc.-
First Approval Date-
27
Clinical Trials associated with Beijing Suncadia Pharmaceuticals Co., Ltd
NCT06723652
/ Not yet recruitingPhase 3
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia
NCT06732648
/ Not yet recruitingPhase 2/3
The Efficacy and Safety of Intravenous HRS8179 for the Prevention and Treatment of Severe Cerebral Edema Following Large Hemispheric Infarction: a Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II/III Clinical Trial
NCT06700083
/ Not yet recruitingPhase 1
Safety, Tolerability, and Pharmacokinetics of Single and Multiple Subcutaneous Injections of SHR-6934 in Healthy Subjects: a Randomized, Double-blind, Dose-escalation, Placebo-controlled Phase I Trial
100 Clinical Results associated with Beijing Suncadia Pharmaceuticals Co., Ltd
Login to view more data
0 Patents (Medical) associated with Beijing Suncadia Pharmaceuticals Co., Ltd
Login to view more data
100 Deals associated with Beijing Suncadia Pharmaceuticals Co., Ltd
Login to view more data
100 Translational Medicine associated with Beijing Suncadia Pharmaceuticals Co., Ltd
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 22 Jan 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
IND Application
1
2
Phase 1
Phase 2
1
2
Phase 3
Other
1
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
SHR-1918
 ( ANGPTL3 )		Homozygous familial hypercholesterolemia
More
Phase 3
HRS-8179
 ( SUR1 )		Brain Edema
More
Phase 2/3
SHR-2004
 ( FXIa )		Venous Thromboembolism
More
Phase 2
HRS-5346
lipoprotein Disorder
More
Phase 1
SHR-6934
Heart Failure
More
Phase 1
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free